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The major histocompatibility complex (MHC) class II transactivator (CIITA) is the master regulatory factor
required for appropriate expression of class II MHC genes. Understanding the expression of CIITA is key to
understanding the regulation of class II MHC genes. This report describes the independent regulation of two
distinct CIITA promoters by cytokines with opposing functions, gamma interferon (IFN-g) and transforming
growth factor b (TGF-b). A functional analysis of deletion mutations of the upstream promoter (promoter III)
identified an IFN-g-responsive region located approximately 5 kb from the transcriptional start site. An in vivo
DNase I hypersensitivity analysis detected a hypersensitive site in this area which supports the relevance of this
region. When the downstream promoter (promoter IV) was studied by in vivo genomic footprinting, IFN-g-
induced changes at putative binding sites for STAT1, interferon regulatory factor 1 (IRF-1), and E-box proteins
were seen. Gel shift and supershift analyses for IRF-1 confirmed the in vivo footprint results. The role of the
IFN-g-inducible transcription factor STAT1 was examined functionally. Although both promoters were con-
trolled by STAT1, promoter-specific regulation was exhibited. The IFN-g response of promoter III was
completely dependent on STAT1 and not IRF-1, while promoter IV was partially activated by IRF-1 in the total
absence of STAT1 expression. While both promoters were affected by TGF-b, activation of promoter III by
IFN-g was more severely diminished by TGF-b treatment. The differential control of CIITA promoters by
TGF-b, IRF-1, and STAT1 may be important in refining regulation of class II MHC genes in different cell types
and under different stimulatory conditions.
The class II major histocompatibility complex (MHC) mol-
ecules present antigenic peptides to CD41 T cells through
interactions with both the T-cell receptor and the CD4 mole-
cule. Presentation of antigenic peptides by class II MHC mol-
ecules requires coexpression of (i) invariant chain (Ii), which
not only binds to the antigen-binding cleft to prevent peptide
binding in the endoplasmic reticulum but also targets class II
MHC molecules to special cellular compartments where for-
eign peptides are loaded, and (ii) the enzymatic HLA-DM
protein, which removes the Ii-derived peptide and facilitates
loading of foreign peptides (9, 10, 13, 15, 31, 33, 48, 56). The
class II MHC, Ii, and DM genes are controlled to different
extents by the master transcriptional regulator, class II trans-
activator (CIITA) (3, 20).
CIITA was initially isolated by complementation cloning of
RJ2.25, an in vitro mutagenized, class II MHC-defective B-cell
line (51). CIITA not only restores class II MHC gene and
antigen expression in RJ2.25 but also restores class II MHC
expression in cells of the BLS-2 cell line (complementation
group A), derived from patients suffering from the bare lym-
phocyte syndrome. Thus, this genetic defect in a subset of bare
lymphocyte syndrome patients resides in the CIITA gene. Cur-
rent evidence from our group shows that the BLS-2 defect,
which involves deletion of a 72-bp CIITA exon, lies in the
inability of the mutant CIITA to undergo nuclear translocation
(7).
CIITA is a transcriptional coactivator that does not bind
DNA yet exhibits a potent and specific effect on class II MHC
gene transcription. The CIITA protein has domains normally
associated with transcriptional activators such as acidic and
proline-, serine-, and threonine-rich domains, and also con-
tains an unusual and important consensus GTP-binding do-
main (5). Recent evidence shows that lack of CIITA results in
a closed chromatin structure in the class II MHC promoter (44,
58). More importantly, reintroduction of CIITA into G3A, a
mutagenized gamma interferon (IFN-g)-unresponsive cell line
that lacks CIITA expression, results in the opening and occu-
pancy of previously closed class II MHC, Ii, and DM promot-
ers (54, 58). The capacity of CIITA to open previously closed
promoters appears to be restricted to IFN-g-responsive cells
and not to B cells. The biochemical mode by which CIITA
functions is poorly understood, although one report shows that
CIITA can interact with RFX5 in a yeast two-hybrid system
(46). Others have shown interactions with Bob1, a B-cell fac-
tor, and with TAFII32, a subunit of the basal transcription
factor TFIID (11, 12, 29). More recently, we have found that
CIITA interacts with the coactivator CREB-binding protein
(17). These multiple interactions may provide a model by
which CIITA exerts its effects on gene transcription.
The expression of CIITA coincides with class II MHC gene
expression, and this feature is distinct from other transcription
factors that control the expression of class II MHC (28). These
other transcription factors, primarily RFX and NF-Y, are ubiq-
uitously expressed and cannot explain the restricted tissue and
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cell distribution of class II MHC. In contrast, the expression of
CIITA is nearly identical to that of class II MHC genes. Two
dominant regulators of class II MHC gene expression also
control CIITA expression. IFN-g upregulates while transform-
ing growth factor beta (TGF-b) suppresses CIITA (4, 6, 24, 37,
52). The physiologic roles of IFN-g and TGF-b in controlling
class II MHC expression are well documented. For example,
TGF-b2/2 gene knockout mice develop severe autoimmune
disease accompanied by the hyperexpression of class II MHC
genes (14, 36, 49). In contrast, manifestations of autoimmunity
are greatly diminished in mice that are both TGF-b2/2 and
I-A2/2 (26), which suggests that many of TGF-b’s effects on
the immune system are mediated via the suppression of class II
MHC expression. Hence, an understanding of the regulation of
CIITA is seminal in the definition of events that lie between
the binding of IFN-g and TGF-b to their respective receptors
and the downstream activation or suppression of class II MHC
genes.
Previously, we and others have found that B-cell-specific
expression of CIITA requires a small promoter region imme-
diately upstream of the transcriptional start site (contained in
pIIIDEL4.CIITA.Luc) (see Fig. 1) (25, 35, 41). Our study
further indicated that IFN-g induction of this promoter is
possible in several different cell types and requires DNA se-
quences located at least 2.5 kb upstream of the start site. This
IFN-g-inducible region was shown to be functional both in the
context of this CIITA promoter and when linked to a heterol-
ogous promoter.
In parallel, another laboratory used RNase protection anal-
ysis to show that the CIITA gene has multiple transcriptional
start sites, a finding indicative of multiple promoters (35).
These authors concluded that the human CIITA gene has four
promoters designated by their location from 59 (upstream) to
39 (downstream) as promoter I, primarily expressed in den-
dritic cells; promoter II, expressed at insignificant levels and
functionally not well understood; promoter III, primarily active
in B cells; and promoter IV, expressed in response to IFN-g
(see Fig. 1A). A comparison of their and our published reports
indicates that the promoter identified in our report corre-
sponds to promoter III of their report. A more careful exam-
ination of their RNase protection data shows us that promoter
III is also IFN-g inducible in a number of different cell types,
including endothelial cells and fibroblasts, although the induc-
ibility of this promoter is weaker than that of promoter IV.
Hence, there may exist two distinct IFN-g-inducible regions
that reside in promoters III and IV, respectively.
The purpose of this report is to resolve the issue of two
distinct IFN-g-inducible promoters for the CIITA gene and to
perform a series of experiments comparing the inducibility of
these promoters. This was achieved by in vivo analyses to
detect changes in the chromatin or the binding of proteins to
specific regions within each promoter. Upon verification of
modifications in the chromatin by either in vivo DNase I hy-
persensitivity or genomic footprint analysis, the promoters
were studied by gel shift analyses and/or in a luciferase re-
porter system. The promoters exhibited differential responses
to the IFN-g-induced transcription factors, STAT1 and IRF-1,
as well as to TGF-b. The implications of two IFN-g-responsive
promoters with distinct patterns of response to cytokines and
transcription factors may explain the complex pattern of class
II MHC expression in different tissues and may have broad
ramifications in tissue-specific immune responses, such as au-
toimmunity and transplantation responses.
MATERIALS AND METHODS
Cell lines. 2fTGH cells are derived from HT 1080 human fibrosarcoma cells
that do not constitutively express class II MHC antigens but express high levels
of these antigens after IFN-g induction. U3A (generously provided by George
Stark, Cleveland Clinic Foundation Research Institute, Cleveland, Ohio) is a
STAT1-defective cell line derived from 2fTGH (39). U3A and 2fTGH cells were
grown in Dulbecco’s modified Eagle’s medium (Gibco BRL) supplemented with
10% fetal calf serum, 2 mM L-glutamine, and penicillin and streptomycin (100
U/ml). Murine P19 embryonal carcinoma cells (CRL-1825; American Type Cul-
ture Collection) were grown in Alpha Eagle’s modified Eagle’s medium (Gibco
BRL) supplemented as described above. U373-MG human glioblastoma multi-
forme cells were grown in McCoy’s 5A medium (Gibco BRL) supplemented as
described above.
Constructs. The isolation of clones containing the promoter regions of the
human CIITA gene as well as the construction of pIIIDEL4.CIITA.Luc (previ-
ously called p668CIITA.Luc), pIIIDEL1.CIITA.Luc (previously p7000-2000CIITA-
.Luc), and pIIICIITA.Luc (previously p7000CIITA.Luc) has been described else-
where (41). To obtain plasmids pIIIDEL2.CIITA.Luc and pIIIDEL3.CIITA.Luc,
2,181-bp XbaI-SphI (for pIIIDEL2.CIITA.Luc) and 1,068-bp XbaI-AccI (for
pIIIDEL3.CIITA.Luc) fragments from the 59 end of pIIICIITA.Luc were cloned
into the KpnI site at the 59 end of the CIITA sequences in pIIIDEL4.CIITA.Luc by
filling in using the Klenow fragment and ligation of the blunted ends. CIITA pro-
moter IV was generated by PCR using Taq polymerase and standard reaction
conditions (Perkin-Elmer Cetus). Oligonucleotides 59-TGAGTTGGAGAGAAAC
AGAG-39 (sense) and 59-CTGCTGGTGGCCTCTC-39 (antisense) were used to
amplify nucleotides 2346 to 150 of the CIITA promoter IV sequence reported by
Muhlethaler-Mottet et al. (35). Extensions (ACGTACAAGCTT) at the 59 ends of
the primers generated HindIII sites that were used to clone the amplified fragment
into the HindIII site of pGL2-Basic (Promega) to create pIVCIITA.Luc. The tem-
plate DNA for the PCR was a human CIITA genomic clone (clone 2) that has been
previously described (41). Oligonucleotides 59-CTCAGCGCTGCAGAAAGAActt
agAAGGGAAAAAGAACTGCGGGGAG-39 (sense; mutations shown in lower-
case type) and 59-TCGAAGTATTCCGCGTAC-39 (antisense) were used in the
PCR that was performed to create the IRF-1 site mutation in CIITA promoter IV.
The template DNA for the PCR was the pIVCIITA.Luc plasmid. The primers were
designed to amplify a region from the PstI site (underlined in the sense primer) in
promoter IV to bp 248 in pGL2-Basic. The mutated amplified fragment was digested
with PstI-XbaI and then substituted for the nonmutated PstI-XbaI fragment in
pIVCIITA.Luc to create pmIRF.IVCIITA.Luc. Similarly, oligonucleotide 59-CTG
CAGAACCAGGCAGTTGGGATGCCACggagtcTAAAGCACGTGGTGGCCA
CAG-39 (sense; mutations shown in lowercase type) was used with the antisense
primer described above to amplify a region from the BstXI site (underlined) in
promoter IV to bp 248 in pGL2-Basic. The mutated amplified fragment was
digested with BstXI-XbaI and then substituted for the nonmutated BstXI-XbaI
fragment in pIVCIITA.Luc to create pmGAS.IVCIITA.Luc. Junctions of plas-
mids pIIIDEL2.CIITA.Luc and pIIIDEL3.CIITA.Luc and the inserts and junc-
tions of pIVCIITA.Luc, pmIRF.IVCIITA.Luc, and pmGAS.IVCIITA.Luc have
been confirmed by DNA sequencing. The pSVISGF2 plasmid, which contains
the human IRF-1 cDNA, was generously provided by Richard Pine, New York
University. To generate the IRF-1 expression plasmid, the human IRF-1 cDNA
was removed from pSVISGF2 as an XbaI-HindIII fragment and subcloned into
the XbaI-HindIII site of pcDNA3 (Promega).
Ligation-mediated PCR DNase I hypersensitivity mapping. The DNase I
hypersensitivity mapping technique used in this study uses ligation-mediated
PCR optimized for amplification of long PCR fragments to detect blunt-ended
DNase I-hypersensitive sites. One million cells were plated in 10-cm-diameter
dishes and either left untreated or treated with IFN-g for 5 h. Cells were
permeabilized with 0.2% saponin in DNase I buffer (15 mM Tris [pH 7.4], 15 mM
NaCl, 60 mM KCl, 3 mM MgCl2, 0.25 M sucrose, 1 mM dithiothreitol). The
permeabilized cells were then treated with DNase I buffer containing 0.05%
saponin and either 20 or 40 U of DNase I (Boehringer Mannheim) for 60 s. The
buffer was removed from the dish, and the cells were lysed and digested by
incubation for 3 h at 37°C in a buffer consisting of 0.15% sodium dodecyl sulfate,
10 mM Tris (pH 7.4), 10 mM EDTA, RNase A (100 mg/ml), proteinase K (400
mg/ml), and 1 mM dithiothreitol. Genomic DNA was then extracted with phenol-
chloroform and was precipitated. Five mg of DNase I-digested genomic DNA or
undigested DNA was ligated with the blunt-ended linker used in the ligation-
mediated PCR protocol (57). One-fifth of the products of the ligation reaction
was then amplified by PCR using Expand High Fidelity DNA polymerase
(Boehringer Mannheim) according to the manufacturer’s recommended condi-
tions. The initial extension time was 3 min. All PCRs used the linker primer
59-GCGGTGACCCGGGAGATCTGAATTC-39 in combination with a CIITA
locus specific primer. For analysis of promoter IV, primer 104CIITA, 59-GATT
CCTACACAATGCGTTGCCTGGCTC-39 (melting temperature [Tm] 5 65°C),
was used. For analysis of promoter III, primer CIITAint, 59-CCTTTCGGTGC
TGATACATGGTTC-39 (Tm 5 63°C), was used. One-fifth of the reaction mix-
ture was loaded onto 1% agarose gels, and the fragments were separated by
electrophoresis, transferred to a nylon membrane (Nytran; Schleicher and
Schuell) and UV cross-linked. For detection of the amplification products, a
probe was generated by using [a-32P]dCTP in PCRs using primers 104CIITA and
CIITAint and the human CIITA genomic clone (mentioned above) as a tem-
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plate. The size of fragments was estimated by using both 1-kb and 100-bp
markers (Gibco BRL), with correction for inclusion of the linker primer at the
end of each fragment.
Transfections and luciferase assay. Transient transfections of 2fTGH and
U3A were performed by the calcium phosphate coprecipitation method (45).
Cells were plated in six-well plates at a density of 6 3 104 cells/well and trans-
fected 24 h later. Three micrograms of reporter construct or 3 mg of reporter
construct in combination with 3 mg of negative control DNA (pcDNA3; Invitro-
gen), STAT1, or IRF-1 expression vector was added to each well, and the dishes
were incubated at 37°C in 5% CO2. After 6 h, the precipitates were removed and
the cells were rinsed twice with phosphate-buffered saline. Culture medium (2 ml
per well) was added, and the plates were incubated for 12 h. During this period
for experiments involving TGF-b treatment, the culture medium was supple-
mented with 10 ng of TGF-b1 (R & D Systems)/ml. After 12 h, culture medium
was removed and replaced with fresh medium, with or without 500 U of recom-
binant human IFN-g (Genentech)/ml. Cells were harvested for luciferase assays
FIG. 1. (A) Map of the 14-kb human CIITA gene fragment that contains both IFN-g-inducible promoters of the CIITA gene. The locations of the transcriptional
start sites of the upstream IFN-g-responsive promoter (promoter III) and the downstream promoter (promoter IV) are shown by arrows. The location of the DNase
I-hypersensitive site that lies approximately 6 kb upstream of the start site of promoter III is marked with an arrowhead. Locations of the DNA fragments used in
reporter constructs described in this report are given (black boxes). Gray boxes indicate the 59 untranslated regions in promoter III and IV constructs. A horizontally
hatched box denotes the location of the 668-bp region previously shown to be required for constitutive basal promoter III activity in B cells (41). Regions that confer
IFN-g inducibility are indicated by diagonally and vertically hatched boxes for promoter III and promoter IV, respectively. Open boxes show the locations of the STAT1
(GAS) and IRF-1 consensus binding motifs in promoter IV. H, HindIII. (B) Deletion mutants that contain DNA sequences located distant to promoter III of CIITA
confer IFN-g inducibility in 2fTGH cells. Transient transfections of 2fTGH cells were performed by calcium phosphate coprecipitation. After 6 h, precipitates were
removed and culture medium was added with or without 500 U of IFN-g/ml. Cells were harvested for luciferase assays 14 h later. Luciferase activity was measured in
RLU per microgram of protein. Fold induction after IFN-g treatment was calculated by dividing the RLU of IFN-g-treated samples by the RLU of untreated samples.
Data shown are the averages of three independent experiments. Error bars represent standard errors of the means.
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14 h later. The STAT1 expression vector (generously provided by James Darnell,
Jr., Rockefeller University, New York, N.Y.) has been previously described (19).
Transient transfections of P19 cells were performed by the calcium phosphate
technique described above with the following modifications: cells were plated in
10-cm-diameter dishes at a density of 5 3 105 cells, each dish received 10 mg of
reporter construct in combination with 10 mg of control DNA or the IRF-1
expression vector, culture medium (10 ml) was added, and cells were harvested
for luciferase assays 14 h later.
Luciferase assays were performed with an LB 953 AutoLumat (EG&G
Berthold) as previously described (2). The protein content of cell extracts was
determined by the Bradford assay (1). Luciferase activity was measured as
relative light units (RLU) per microgram of protein. Fold induction after treat-
ments was calculated by dividing the luciferase activity of IFN-g-treated samples
by the RLU of untreated samples.
In vivo genomic footprinting. Dimethyl sulfate (DMS) treatment of cells and
genomic DNA preparation were performed as previously described (40).
Cleaved genomic DNA was amplified by using a ligation-mediated PCR protocol
(57, 59). Ten million cells were treated with 500 U of recombinant IFN-g
(Genzyme)/ml for 4, 8, or 24 h before DMS treatment and genomic DNA
isolation. Three CIITA locus-specific primers were used to amplify cleaved
fragments from the upper strand of CIITA promoter IV: CIITA4 up1, 59-CTA
CCGCTGTTCCCCG-39 (Tm5 61°C); CIITA4 up2, 59-GCGGCAAGTCTGTG
GCAGCTC-39 (Tm 5 65°C); and CIITA4 up3, 59-GCGGCAAGTCTGTGGCA
GCTCGTC-39 (Tm 5 68°C). The ligation-mediated PCR procedure was also
performed for the lower strand, but no significant protections or enhancements
were observed. The primers used for the lower strand were CIITA4 lo1, 59-GG
GCCTGGGACTCTC-39 (Tm 5 61°C); CIITA lo2, 59-GGGCTGGCCACTGT
GAGGAAC-39 (Tm 5 65°C); and CIITA lo3, 59-GGCTGGCCACTGTGAGG
AACCGACTG-39 (Tm 5 69°C).
Preparation of nuclear extracts and gel shift analyses. Nuclear extracts were
prepared by the method of Schreiber et al. from 2fTGH cells, uninduced and
induced with 500 U of IFN-g/ml for 14 h (47). The WT-IRF1/2CIITA oligonu-
cleotide probe was as follows: 59-CTGCAGAAAGAAAGTGAAAGGGAAAA
AGAACT-39. The additional oligonucleotide probes used as cold competitors
were MT-IRF1/2CIITA, 59-CTGCAGAAAGAActtagAAGGGAAAAAGAAC
T-39, and IRF-E, 59-CGGCCGCTTTCGATTTCGCTTTCCCCTAAATGGCT
G-39, an oligonucleotide that contains an inverted IRF-1-binding site (55). An-
tibodies were purchased from Santa Cruz Biotechnology. Gel shift analysis was
performed as previously described (55). Briefly, 5 mg of nuclear extract and 2.5 3
1022 pmol of annealed and 32P-labeled oligonucleotide probe (;100,000 cpm)
were incubated in a reaction mixture containing 50 mM KCl, 5 mM NaCl, 5%
glycerol, 10 mM Tris (pH 7.9), 1.5 mM MgCl2, 1 mM dithiothreitol, and 2 mg of
poly(dI)(dC) for 20 min at room temperature. Antibodies were incubated with
nuclear extracts in the reaction mixture for 30 min on ice before the addition of
the probe. Complexes were resolved by electrophoresis in 5% acrylamide-bisac-
rylamide (29:1) gels run in 0.53 Tris-buffered EDTA (TBE) at 4°C and 20 mA.
RESULTS
Functional analyses of deletion mutations of promoter III
map an IFN-g-responsive region to the distal end of this 7-kb
region. The intent of this report was to understand the func-
tional differences of the two IFN-g-responsive promoters (pro-
moter III and promoter IV) of CIITA. This is important be-
cause different cell types may selectively utilize these two
promoters, resulting in distinct patterns of immune stimulation
in vivo. A previous report from our laboratory showed that
pIIICIITA.Luc, which contains a large 7-kb region upstream of
promoter III, included an IFN-g-responsive region. To de-
FIG. 2. DNase I hypersensitivity analyses reveal hypersensitive sites in the
proximal promoters of both promoters III and IV and an additional long-range
hypersensitive site for promoter III. (A) Summary of hypersensitivity analysis
and graphic representation of the CIITA genomic region showing the location of
the primers and probe that were used for detection. The hatched region repre-
sents the probe used for Southern blot hybridization. The small arrows above
(primer 104CIITA) and below (primer CIITAint) the hatched region indicate
the locations of the primers used for the PCR. (B) Southern blot analysis of
PCR-amplified products using primer CIITAint to detect promoter III-associ-
ated hypersensitive sites. The start site of the promoter is designated by a filled
arrow to the right of the panel. Estimated positions of the hypersensitive sites are
indicated with open arrows. Lanes 1 and 2 represent results for uninduced cells
that were treated with 20 and 40 U of DNase I, respectively. Lanes 3 and 4
represent results for cells that were induced with IFN-g for 5 h and treated with
20 and 40 U of DNase I, respectively. (C) Southern blot analysis of PCR-
amplified products with primer 104CIITA to detect promoter IV-associated
hypersensitive sites.
FIG. 3. The in vivo footprint of CIITA promoter IV reveals protein-DNA
contacts near the putative STAT1- and E-box-binding sites and within the IRF-1
site. The sequence of the promoter region is shown with the relevant cis-elements
framed. Genomic footprints of the upper strand are shown in the lower panel.
Lane 1 represents genomic DNA methylated in vitro to reveal the complete
guanine ladder. Lanes 2 through 5 show the results of a time course of IFN-g
treatment using DNA from cells treated with DMS in culture. Open arrows
indicate bases that are protected from modification. Filled arrows indicate bases
for which modification is enhanced.
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lineate this region, a series of internal deletion mutations
(Fig. 1A) were produced. Three deletion constructs contain-
ing the most distal 3,563, 2,181, and 1,068 bp of DNA within
the 7-kb fragment were linked to 668 bp of basal CIITA
promoter III sequence and cloned into the luciferase re-
porter gene vector, pGL2-Basic. These plasmids were des-
ignated pIIIDEL1.CIITA.Luc, pIIIDEL2.CIITA.Luc, and
pIIIDEL3.CIITA.Luc, respectively. As shown in Fig. 1B, all
FIG. 4. IRF-1 binds to the proximal IFN-g-inducible promoter (promoter
IV). (A) Gel shift analysis indicates that one protein complex is induced by
IFN-g (lane 2 versus lane 3) (arrow). Nuclear extracts were from 2fTGH cells
induced with 500 U of IFN-g/ml for 14 h (IFN-g) and uninduced cells (UNT).
The probe spans the IRF-1/IRF-2 site (Fig. 1A; Materials and Methods). Lane
1 contains probe only. Oligonucleotide competitors are designated in the top row
and are used at 200-fold molar excess (2003). Abbreviations: WT, homologous
CIITA IRF-1/IRF-2 competitor; MT, cold competitor with a mutated IRF-1/
IRF-2 site; IRF-E, cold competitor with the IRF-1-binding site of the TAP1
gene. NUC. EX., nuclear extract. (B) Incubation with anti-IRF-1 induces a
supershifted complex (star) and reduces the formation of the inducible complex
(arrow). Antibodies are indicated at the top. Abbreviations: AB, antibody; NS,
normal serum. (C) The IRF-1 site is required for induction of promoter IV by
IFN-g. Transient transfections of 2fTGH cells were performed by calcium phos-
phate coprecipitation using plasmids containing wild-type CIITA promoter IV
(pIVCIITA.Luc) and promoter IV with a mutated IRF-1 site (pmIRF.IVCIITA
.Luc). After 6 h, precipitates were removed and culture medium was added with
or without 500 U of IFN-g/ml. Cells were harvested for luciferase assays 14 h
later. Fold induction after IFN-g treatment was calculated by dividing the RLU
of IFN-g-treated samples by the RLU of untreated samples. Data shown are the
averages of three independent treatment groups. Error bars represent standard
errors of the means. This experiment has been repeated with similar results.
FIG. 5. Regulation of the IFN-g-inducible promoters by STAT1 and IRF-1.
Transient transfections of U3A and P19 cells with the indicated plasmids
(pIIIDEL1.CIITA.Luc for promoter III, pIVCIITA.Luc for promoter IV, pm-
GAS.IVCIITA.Luc for promoter IV-mtGAS, STAT1 for STAT1 expression
plasmid, pcDNA3 for CTR, and IRF-1 for IRF-1 expression plasmid) were
performed by calcium phosphate coprecipitation. (A) U3A is a STAT1-defective
cell line derived from 2fTGH. Cultures were untreated (UNT) or treated with
500 U of human IFN-g/ml (IFN) and harvested 14 h later. Luciferase activity was
measured as RLU per microgram of protein. Error bars represent standard
errors of the means. No IFN-g induction was seen for control plasmids. These
experiments have been repeated with similar results. (B) P19 is a murine em-
bryonal carcinoma cell line that does not express IRF-1. Precipitates were re-
moved after 6 h, and fresh culture medium was added. Cells were harvested for
luciferase assays 24 h later. Luciferase activity was measured as RLU per mi-
crogram of protein. Results shown are the averages of three cultures per group.
Error bars represent standard errors of the means. These experiments have been
repeated with similar results. (C) U3A cells were cotransfected with the indicated
plasmids. Cultures were untreated or treated with 500 U of human IFN-g/ml and
harvested 14 h later. Luciferase activity was measured as RLU per microgram of
protein. Error bars represent standard errors of the means. No IFN-g induction
was seen for control or IRF-1 plasmids (data not shown). These experiments
have been repeated with similar results.
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three constructs were IFN-g inducible when transiently
transfected into human 2fTGH fibroblasts, although the in-
ducibility seen for plasmid pIIIDEL3.CIITA.Luc was repro-
ducibly less. This maps the minimal IFN-g-responsive re-
gion to the distal approximately 1 kb, although the
additional sequences found in pIIIDEL2.CIITA.Luc aug-
ment the response. The pGL2-Basic vector plasmid and
pIIIDEL4.CIITA.Luc, which contains the minimal B cell-
promoter of CIITA promoter III, were used as negative
controls. The full-length IFN-g-inducible promoter III plas-
mid, pIIICIITA.Luc, which was previously shown to retain
full IFN-g inducibility, was used as a positive control.
DNase I hypersensitivity analyses reveal sites located ap-
proximately 5 kb upstream of the transcriptional start site of
promoter III and immediately adjacent to the start sites of
both promoter III and promoter IV. Another way to determine
the functional importance of a DNA sequence is to examine
for in vivo hallmarks of protein-DNA interactions as revealed
either by DNase I hypersensitivity analysis or by genomic foot-
printing. Our group has previously reported that a 6-kb region
upstream of the transcriptional start site of promoter III me-
diates the IFN-g response (41). New data presented in Fig. 1B
further showed that the most upstream 1 kb of DNA contains
important regulatory sequences. The DNase I hypersensitivity
method was used to indicate the locations of potential regula-
tory protein-DNA interactions, as this method can be used to
scan large regions of DNA for structural changes in chromatin.
A modified DNase I hypersensitivity method using ligation-
mediated PCR with optimization for amplification of long
PCR fragments was established. The analysis was performed
with U373-MG cells, one of several cell types for which we
have previously shown the IFN-g responsiveness of this region
(41). Double-stranded breaks at hypersensitive sites were li-
gated to the blunt-ended linker commonly used in the in vivo
genomic footprinting technique (57). Two CIITA locus-spe-
cific primers were used in combination with a linker-specific
primer to amplify fragments ending with a hypersensitive site.
The CIITA-specific primers were also used to generate a probe
for Southern blot analysis of the amplified fragments (Fig. 2A).
Amplification using an intron-specific primer allowed detec-
tion of hypersensitive sites 59 of the promoter III start site. A
DNase I-hypersensitive site was consistently observed approx-
imately 5 kb upstream of this initiation site (Fig. 2B, lanes 1
and 3). This site was detectable before induction with IFN-g,
and upon induction a slight increase in sensitivity is observed.
The location of the hypersensitive site correlates with the func-
tional analysis shown in Fig. 1B, which shows IFN-g inducibil-
ity residing in the furthest 1 kb of this 6-kb region upstream of
promoter III. Upon using a higher concentration of DNase I,
the 5-kb site disappeared and several hypersensitive sites were
more clearly visible in the vicinity of the transcriptional start
site (Fig. 2B, lanes 2 and 4). Promoter IV was analyzed by
amplification in the downstream direction with a primer spe-
cific for sequences near the initiation site of promoter III (Fig.
2A). Hypersensitive sites were detected very close to the tran-
scriptional start site for promoter IV (Fig. 2C). Again, hyper-
sensitive sites were detectable before induction, but an in-
crease in DNase I sensitivity was clearly observed after 5 h of
IFN-g treatment (compare lanes 1 and 2 to 3 and 4).
Genomic footprint analysis detects changes at putative
STAT1, IRF-1, and E-box binding sites in promoter IV. In
contrast to the large span of endogenous DNA that is required
to demonstrate IFN-g inducibility for promoter III, the IFN-
g-responsive region of promoter IV consists of approximately
400 bp of DNA located downstream of promoter III (35). In
addition, promoter IV uses a different transcriptional start site
(Fig. 1A). In vivo genomic footprint analysis is the method of
choice to define physiologically relevant sequences within such
a relatively small region. Methylated genomic DNA was ob-
tained from U373-MG cells that had either remained un-
treated or had been treated with IFN-g for 4 to 24 h. IFN-g
treatment resulted in significant protections in promoter IV at
three predominant sites: adjacent to a putative STAT1-binding
site (GAS), within a putative IRF-1/IRF-2 site, and adjacent to
an E-box motif (Fig. 3). Protection at the guanine residue that
lies between the GAS and E-box sites was only present in
IFN-g-induced samples. These contacts were sustained even
FIG. 6. IFN-g induction of the promoter IV is greater than that of promoter
III. Transient transfections of 2fTGH cells were performed by calcium phosphate
coprecipitation. After 6 h, precipitates were removed and culture medium was
added with or without 500 U of IFN-g/ml. Cells were harvested for luciferase
assays 14 h later. Luciferase activity was measured as RLU per microgram of
protein. Fold induction after IFN-g treatment was calculated by dividing the
RLU of IFN-g-treated samples by the RLU of untreated samples. Data shown
are the averages of four independent experiments. Error bars represent standard
errors of the means.
FIG. 7. TGF-b suppresses both promoters, but suppression of promoter III
is more pronounced. Transient transfections of 2fTGH cells were performed by
calcium phosphate coprecipitation. After 6 h, precipitates were removed and
culture medium was added with (TGF) or without (UNT) 10 ng of TGF-b/ml.
After 12 h, culture medium was changed to medium with (IFN) or without
(UNT) 500 U of IFN-g/ml. Cells were harvested for luciferase assays 14 h later.
Luciferase activity was measured as RLU per microgram of protein. Data shown
are the averages of three cultures per group. Error bars represent standard errors
of the means. These experiments have been repeated with similar results.
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after 24 h of IFN-g treatment. The only protections that were
located directly over a putative transcription factor binding site
were found in the IRF-1/IRF-2 site. There was a small amount
of protection of this site before induction, but IFN-g treatment
resulted in a significant increase in the amount of protection.
Analyses of methylated DNA obtained from another IFN-g-
responsive cell line, 2fTGH, showed similar protections, while
analyses of DNA from human Raji B cells showed no protec-
tions, which is consistent with B cells using promoter III and
not promoter IV (data not shown).
Gel shift and supershift analyses verify the binding of IRF-1
to its cognate binding site in promoter IV. Gel shift and su-
pershift analyses were performed to identify the proteins that
interact with the in vitro-footprinted sequence. During the
preparation of this manuscript, another group also demon-
strated STAT1 binding to promoter IV in vitro (34). In the
present study we examined actual binding of IRF-1 to the
putative IRF-1/IRF-2-binding site. This is important because
this site is also a potential IRF-2-binding site or might be
recognized by yet another member of the increasingly large
IRF family of DNA binding proteins (38). Furthermore, func-
tional analyses revealed a more significant function for the IRF
site than the STAT1-binding site (see below). An in vitro gel
shift analysis was performed and demonstrated the formation
of a complex on this site in response to IFN-g treatment (Fig.
4A, compare lanes 2 and 3). Specific cold competitors consist-
ing of either the wild-type IRF-binding site from promoter IV
(lane 4) or a consensus IRF site (lane 6) eliminated the for-
mation of this band, while a competitor with a mutated IRF-
1/IRF-2-binding site did not (lane 5). Preincubation of the
nuclear extracts with an anti-IRF-1 antibody resulted in a su-
pershifted band, while preincubation with normal serum, iso-
type-matched antibodies against IRF-2, or the p52 NF-kB sub-
unit did not (Fig. 4B, lane 4 versus lanes 3, 5, and 6). As shown
in Fig. 4B, nuclear extracts were preincubated in the reaction
mixture (with or without antibody) for 30 min. This preincu-
bation led to a decrease and/or slight shift in the location of
nonspecific bands versus the pattern seen in Fig. 4A, for which
there was no preincubation. There are also slight differences in
the nonspecific bands between lanes shown in Fig. 4B. The
difference between lanes 2 and 3 probably reflects the differ-
ence in the protein content of the mixture in lane 3, which
received added protein from the normal serum. Similarly,
slight changes in nonspecific bands between lane 2 and lanes 4
to 6 probably reflect differences in protein content between the
normal serum and the antibodies. In addition, a pmIRF.CIITA
.Luc plasmid bearing a mutation of this IRF-1- binding site was
not inducible by IFN-g in transfection experiments performed
in 2fTGH fibroblasts (Fig. 4C). Together, these results provide
strong evidence that the site is required for induction and can
indeed be recognized by IRF-1.
A comparison of the two promoters reveals that promoter IV
is responsive to both STAT1 and IRF-1 but promoter III is not
responsive to IRF-1. Two predominant transcription factors
which mediate the positive regulatory functions of IFN-g are
STAT1 and IRF-1. The STAT1 protein resides in the cyto-
plasm in a nonactive form. Upon IFN-g binding, the chains of
the IFN-g receptor are cross-phosphorylated by JAK kinases.
STAT1 is recruited, undergoes phosphorylation, homodimer-
izes, and translocates to the nucleus where it binds a consensus
IFN-g activation sequence (GAS) and induces gene transcrip-
tion. Thus, activation of STAT1 by IFN-g does not require de
novo protein synthesis. In contrast, the transcription of IRF-1
is induced by IFN-g treatment and requires both de novo
transcription and protein synthesis. In fact, a GAS element is
present in the promoter of the IRF-1 gene and STAT1 is a
primary activator of IRF-1 transcription (43).
To more directly assess the involvement of IRF-1 and/or
STAT1 in the regulation of CIITA promoters III and IV,
mutant cell lines that selectively lack functional IRF-1 and
STAT1 activities were used. U3A fibroblasts selectively lack
STAT1 activity. The lack of functional STAT1 resulted in
greatly reduced activation by IFN-g of both promoter III
(pIIIDEL1.CIITA.Luc) and promoter IV (pIVCIITA.Luc)
(Fig. 5A, CTR data). Introduction of a vector constitutively
expressing STAT1 and IFN-g treatment resulted in a 20-fold
induction of promoter IV and a 3.3-fold induction of promoter
III by IFN-g. Fold induction after IFN-g treatment was calcu-
lated by dividing the luciferase activity of IFN-g-treated sam-
ples by the activity of untreated samples. The induction of
pIIIDEL1.CIITA.Luc by STAT1 has been previously reported
by our laboratory (41). Interestingly, a promoter IV construct
(pmGAS.IVCIITA.Luc) in which the GAS motif (TTCTGAT
AAA) was mutated to the sequence GGAGTCTAAA retained
sevenfold inducibility by IFN-g (Fig. 5A, mutGAS). This find-
ing suggests that the GAS site per se may not be absolutely
required for induction. Since the pmGAS.IVCIITA.Luc con-
struct still retains the wild-type IRF-1 site, the requirement for
STAT1 may be related at least partly to the reliance on STAT1
for induction of IRF-1 in these cells. An ;50% decrease in
FIG. 8. Model of the regulation of class II MHC genes by IFN-g. B-cell
constitutive expression of CIITA is mediated by the proximal 59-flanking se-
quences of promoter III (horizontally hatched box). In contrast, induction of this
promoter by IFN-g is mediated by distal upstream sequences (diagonally hatched
box). Binding of IFN-g to its receptor activates JAK kinases which results in
phosphorylation of STAT1. It is likely that STAT1 activation is accompanied by
activation of the CIITA promoter directly via STAT1 binding to sequences in this
region (black arrow). In addition, STAT1 activation induces transcription of
CIITA promoter IV both by binding directly to sequences in this promoter (open
arrow) and by inducing the transcription of IRF-1 that is also required for
promoter activation (dashed arrow). CIITA then activates transcription of the
class II MHC, Ii, and DM genes through common sequences found in the
promoter regions of these genes. Binding of TGF-b to its receptor interferes with
CIITA gene expression by attenuating the basal activity of both CIITA promot-
ers. It is likely that suppression by TGF-b occurs by a mechanism that is distinct
from the pathway of induction by IFN-g.
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induction by IFN-g of the activity of pmGAS.IVCIITA.Luc vs
pIVCIITA.Luc was also seen in 2fTGH cells (data not shown).
To assess the involvement of IRF-1 in the control of the two
CIITA promoters, these promoter-reporter constructs were
transfected into the IRF-1-deficient embryonal carcinoma cell
line P19 (Fig. 5B). The luciferase activity of the promoter III
plasmid, pIIIDEL1.CIITA.Luc, was not enhanced when co-
transfected with an IRF-1 expression vector into P19 cells. In
fact it was consistently less than the activity seen in cells co-
transfected with the pcDNA3 control vector (Fig. 5B). In
contrast, cotransfection with IRF-1 resulted in a dramatic en-
hancement of the luciferase activity driven by promoter IV.
This clearly indicates that promoter IV, unlike promoter III,
requires IRF-1 for induction.
Although data presented in Fig. 5A shows that STAT1 plays
an important role in the control of promoter IV, an extensive
mutation of the STAT1-binding site lowered induction by only
;50%. In light of the important role IRF-1 plays in activating
promoter IV (Fig. 5B), a likely explanation is that the primary
route by which STAT1 controls CIITA promoter IV is indi-
rectly through activation of IRF-1 gene transcription. To fur-
ther investigate the dependence of promoter IV for IRF-1, the
promoter IV luciferase constructs were cotransfected with an
the IRF-1 expression plasmid into U3A cells (Fig. 5C). The
activity of the promoter IV construct was activated 3.6-fold by
IRF-1 expression in these cells, which lack STAT1 expression.
Additionally, the pmGAS.IVCIITA.Luc was responsive to
IRF-1 expression (6.7-fold) (Fig. 5C, mtGAS), which supports
the possibility that the STAT1 activation of IRF-1 is an impor-
tant role of STAT1 in promoter IV activation.
The IFN-g induction of CIITA promoter IV is greater than
that of promoter III. The extent of activation by IFN-g for both
promoters was examined by a comparison of reporter con-
structs containing either promoter III (pIIIDEL1.CIITA.Luc)
or promoter IV (pIVCIITA.Luc) fused to the luciferase re-
porter gene. While both promoters contain IFN-g-responsive
sequences, the inducibility of promoter IV was consistently at
least twofold greater than that of promoter III in the 2fTGH
cells (Fig. 6). The pGL2-Basic plasmid is a promoterless neg-
ative control vector.
Both CIITA promoters are suppressed by TGF-b, but the
suppression of promoter III is more complete. Suppression of
CIITA transcription by TGF-b is an important route by which
class II MHC hyperexpression is prevented in physiologic con-
ditions (24, 37). We tested the effect of TGF-b on the reporter
constructs bearing promoter III (pIIIDEL1.CIITA.Luc) or
promoter IV (pIVCIITA.Luc) sequences. As shown in Fig. 7
(lanes 3 and 4), the promoter III construct was inducible by
IFN-g and this induction was almost completely suppressed by
TGF-b. While promoter IV was also inducible by IFN-g,
TGF-b lowered the luciferase activity of pIVCIITA.Luc by
only 50% (lanes 7 and 8). Treatment with TGF-b alone low-
ered the basal activity of both promoter III (41) and promoter
IV, which indicates that TGF-b may interfere with promoter
activity even in the absence of IFN-g (compare lanes 1 and 2
and lanes 5 and 6). The higher basal activity seen in this
experiment for the promoter III plasmid versus the promoter
IV plasmid was not a consistent finding, but the more intense
suppression of promoter III by TGF-b was a consistent finding.
DISCUSSION
The induction of genes by the type I and II IFNs has been
extensively studied and remains a foundation for our under-
standing of other cytokine pathways. Through elegant bio-
chemistry, somatic mutagenesis, and gene complementation,
many of the molecular mediators have been defined. For the
type II IFN pathway, it is well known that IFN-g binds to its
cognate receptor, resulting in receptor phosphorylation and
the docking of the STAT1 protein. STAT1 is in turn phosphor-
ylated, and this modification leads to the formation of a ho-
modimer (8) (Fig. 8). The homodimer is then translocated into
the nucleus to bind DNA promoter elements that activate gene
expression. On another level, the IRF-1 transcription factor
has a STAT1-binding site in its promoter and is dependent on
STAT1 for its transcriptional activation (43). Thus, STAT1 and
IRF-1 are two prominent transcriptional mediators of the
IFN-g pathway.
Although many of the players in the IFN-g pathway have
been defined, one major unresolved issue in the pathway of
IFN-g-induced gene activation is the induction of class II
MHC genes. We and others have shown more than a decade
ago that the promoter sequences that mediate IFN-g induction
of class II MHC genes contain the W, X, and Y motifs (16, 28,
53). None of these motifs resemble any other IFN-g consensus
sequences that have been described. Using somatic genetics,
two other groups have identified cell lines that are selectively
defective in the IFN-g induction of class II MHC genes but not
other IFN-g-responsive genes (27, 30). Together, these data
indicated that the induction of class II MHC genes requires
molecular mediators that are unique to this pathway. On the
other hand, the analysis of in vitro-generated cell lines indi-
cated that the lack of STAT1 and IRF-1 leads to the lack of
and lowering of class II MHC expression, respectively. These
studies clearly demonstrated that these classical molecules, iden-
tified in the IFN-g induction pathway, are critical for the induc-
tion of class II MHC genes by IFN-g (18, 32, 50). Therefore, class
II MHC gene induction must rely on the presence of STAT1 and
IRF-1, yet its own IFN-g-responsive promoter sequences do not
contain apparent STAT1 or IRF-1 binding sites.
The identification of the CIITA molecular provided the cru-
cial missing link in the elucidation of this pathway. CIITA per
se is induced by IFN-g treatment (4, 6, 52), and its expression
is greatly reduced in STAT12/2 gene knockout mice (32) and
decreased in IRF-12/2 gene knockout mice (18). How STAT1
and IRF-1 control the CIITA promoter is one of the important
questions addressed by the present report. Data presented
here show that the answer is complex. The CIITA gene has two
IFN-g-responsive promoters: one is contiguous with the B-cell
promoter (promoter III); a second uses a different transcrip-
tional start site and lies downstream of the B-cell promoter
(promoter IV) (Fig. 8). The IFN-g responsiveness of the
former is the weaker of the two when assayed in vitro, although
it is clearly responsive to the addition of either IFN-g or
STAT1 but not IRF-1. It is contained in a region that is located
as far as 6 kb away from the B-cell transcriptional start site. In
contrast, promoter IV yields a stronger IFN-g response in
vitro, is well contained, responds to the addition of IFN-g, and
requires STAT1 and IRF-1 for optimal gene expression. The
two promoters show differences in the vigor of their response
to IFN-g in vitro, but it should be noted that many important
distally located promoter regions were not initially recognized
until transgenic mice were used in their analysis. In contrast to
in vitro analyses, such distal sequences are frequently critical
for gene expression in vivo. It will be of interest to determine
the respective roles of these two promoters in vivo.
The differential strengths of these two promoters may also
be related to their dependence on the STAT1 and IRF-1 fac-
tors. While both STAT1 and IRF-1 activate promoter IV,
promoter III is only activated by STAT1 (Fig. 8). A coopera-
tively between STAT1 and IRF-1 may be the reason for the
enhanced response of promoter IV to IFN-g. Interestingly, an
438 PISKURICH ET AL. MOL. CELL. BIOL.
examination of sequence of the IFN-g-responsive region of
promoter III has revealed two potential GAS sites (data not
shown). The activation of STAT1 is an immediate response
and does not require protein synthesis, while the activation of
IRF-1 is a secondary response that requires protein synthesis
and prior activation of other molecules, including STAT1. It
has been shown that STAT1 mediates a faster IFN-g response,
while IRF-1 mediates a slower one. The availability of two
promoters with differential responses to IRF-1 but similar re-
sponses to STAT1 may provide a mechanism to allow the fine
tuning of class II MHC gene induction in different tissues.
Prolonged expression of class II MHC in tissues that might be
prone to autoimmune recognition would not be beneficial to
the host, and these might be prevented if the tissue favors the
use of promoter III and not IV. On the other hand, sustained
class II MHC induction might be preferential in the elimina-
tion of pathogens, and both promoters might then be utilized.
It is of interest that a careful examination of a previous report
indicates to us that IFN-g induces promoter III in some cells
but not others (35). It is important to determine the differential
usage of promoters III and IV by cells in various physiologic
states that lead to heightened class II MHC expression, such as
autoimmune disorders and immune activation by pathogenic
or allogenic foreign antigens.
During the preparation of this manuscript, another group
reported the induction of promoter IV (34). Their and our
reports are in agreement as to the induction of promoter IV by
IFN-g. Gel shift and supershift analyses in this report addi-
tionally show the binding of IRF-1 to the CIITA promoter and
the critical role of IRF-1 in activating promoter IV. In vivo
footprint analyses shown in this report lend further credence to
the physiologic importance of the IRF-1 target site of pro-
moter IV in intact cells. The involvement of both of these
factors was further shown in the present report by the use of
IRF-1- and STAT1-negative cell lines. Our study significantly
extends the former findings by demonstrating that although the
IFN-g-induced response can be mediated by both promoters
III and IV, the two show differential dependency on STAT1
and IRF-1 (Fig. 8).
In contrast to the IFN-g pathway, the induction or inhibition
of genes by TGF-b is not well understood. Several early me-
diators of this pathway have been well studied, and it is gen-
erally accepted that the Smad2, Smad3, and Smad4 proteins
are involved, as all three molecules are required for the phys-
iologic function of TGF-b (22). More recently, two proteins
termed FAST-1 and FAST-2 that also participate in this path-
way have been identified (23, 60). Although it is currently a focus
of much research, the exact mechanism(s) of TGF-b-induced
gene expression is not yet well defined. Some studies have shown
that TGF-b can activate AP-1-containing sequences (21); how-
ever, the role of AP-1 in the expression of genes that are biolog-
ically activated by TGF-b is less well established.
Even less understood is the process by which TGF-b sup-
presses gene expression, and the study of suppression of CI-
ITA transcription by TGF-b could provide important insight
into this. The impetus for understanding the suppression of
class II MHC gene expression by TGF-b is strong, attributed to
the physiologic importance of this suppression. The study of
TGFb2/2 gene knockout mice demonstrated that the primary
phenotype of these mice is the existence of hyperactivated
T-cell responses. To determine if such responses are due to a
lack of class II MHC downregulation due to the absence of
TGF-b, TGF-b2/2 I-A2/2 double knockout mice were pro-
duced and found not to exhibit the hyperactivated T-cell state
(26). This finding provides strong evidence that an important
biologic role of TGF-b is to reduce the level of class II MHC
expression. Uncontrolled elevation of class II MHC expression
in the absence of TGF-b leads to T-cell activation and patho-
logic sequelae.
In light of the important physiologic context of class II MHC
gene suppression by TGF-b, the present study shows that its
negative regulation of class II MHC occurs through the sup-
pression of both CIITA promoters III and IV (Fig. 8). The
suppression of promoter III is more complete than that of
promoter IV, which likely explains the divergent pattern of
TGF-b suppression of class II MHC found in different cell
types. Presumably, cells that preferentially use promoter III
would be more susceptible to TGF-b suppression. Preliminary
data indicates that the basal 668-bp region within promoter III
is sufficient to mediate the suppression of basal activity by
TGF-b (42). With this finding, the small region in each of these
two promoters that mediates TGF-b suppression is well de-
fined, such that detailed mutagenesis is feasible, and should
provide important insights toward understanding how TGF-b
suppresses class II MHC gene expression. Importantly, this
provides a unique model for understanding how TGF-b sup-
presses genes that are physiologically relevant.
In conclusion, this report provides a comprehensive analysis
of how two crucial cytokines control the expression of the
CIITA gene. These data provide important information linking
the binding of cytokines to receptors at cell surfaces to the
induction or suppression of CIITA, leading ultimately to the
alteration of class II MHC gene expression. Both the activator,
IFN-g, as well as the repressor, TGF-b, can alter the promoter
activity of CIITA. In turn, alterations in CIITA expression
control the expression of class II MHC molecules, as well as
other molecules important in class II MHC antigen presenta-
tion. The IFN-g pathway utilized for CIITA promoter activa-
tion is complex and may reflect the nature of class II MHC
gene regulation in different tissues and under different physi-
ologic conditions. The TGF-b-mediated suppression of class II
MHC may be utilized to dissect the poorly understood process
of TGF-b-mediated gene repression.
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